Elite Pharmaceuticals, Inc. (ELTP)
| Market Cap | 554.75M |
| Revenue (ttm) | 84.04M |
| Net Income (ttm) | -4.31M |
| Shares Out | 1.07B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,623,217 |
| Average Volume | 2,606,813 |
| Open | 0.5700 |
| Previous Close | 0.5710 |
| Day's Range | 0.5000 - 0.5720 |
| 52-Week Range | 0.1626 - 0.8194 |
| Beta | 0.24 |
| RSI | 36.29 |
| Earnings Date | Jun 27, 2025 |
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; P... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2025 Earnings Conference Call July 1, 2025 11:30 AM ET Company Participants Carter J. Ward - CFO, Secretary & Treasurer Nasrat Hakim - Chairman, CEO & Presi...
Elite Pharmaceuticals reports FY results
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialt...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025 Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ...
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufactu...
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, t...
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, an...
Elite Pharmaceuticals Inc (ELTP) Q3 2025 Earnings Call Highlights: Record Revenue Growth Amid ...
Elite Pharmaceuticals Inc (ELTP) Q3 2025 Earnings Call Highlights: Record Revenue Growth Amid Operational Challenges
Q3 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Q3 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Elite Pharmaceuticals Inc Reports Q3 2025 Revenue of $14.4 Million Amid Shipment Delays
Elite Pharmaceuticals Inc Reports Q3 2025 Revenue of $14.4 Million Amid Shipment Delays
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025 Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmac...
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products...
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products,...
Elite Pharmaceuticals Inc (ELTP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Elite Pharmaceuticals Inc (ELTP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Product Pipeline Expansion
Elite Pharmaceuticals receives FDA approval on its NDA for ADHD treatment
Q2 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Q2 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manuf...
Elite Pharmaceuticals, Inc. (ELTP) Q2 2025 Earnings Conference Call Transcript
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2025 Earnings Conference Call November 15, 2024 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Carter Ward - CFO Conference Call Particip...
Elite Pharmaceuticals Inc Reports $18.9 Million Revenue and $3. ...
Elite Pharmaceuticals Inc Reports $18.9 Million Revenue and $3.5 Million Operating Profit for Q2 FY2025
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharma...
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health
Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products,...
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, ...
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, ...